Merck & Co., Inc., known as MSD Animal Health outside the United States and Canada, has announced that its new product, BRAVECTO® QUANTUM, has received approval from the U.S. Food and Drug Administration (FDA). This once-yearly injectable treatment provides dogs with year-round protection against fleas and ticks. The product is expected to be available in veterinary clinics and hospitals across the United States by August 2025. BRAVECTO QUANTUM, which utilizes a unique composition of fluralaner, has already been approved in more than 50 countries, including Australia, New Zealand, and the European Union. The product has been recognized with awards for its innovative approach to pet care.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.